Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

Author(s): Marcin Dzienis, MD1; Juan Cundom, MD2; Christian Sebastian Fuentes, MD3; Anna Spreafico, MD4; Melanie Nordlinger, MD5; Andrea Viviana Pastor, MD6; Erin Alesi, MD7; Anterpreet Neki, MD8; Andrea S. Fung, MD, PhD9; Iane Pinto Figueiredo Lima, MD10; Peter Oppelt, MD11; Geraldo Felicio da Cunha Junior, PhD12; Barbara Burtness, MD13; Fabio Andre Franke, MD14; Jennifer E. Tseng, MD15; Abhishek Joshi, MD16; Joy McCarthy, MD17; Ramona Swaby, MD18; Yulia Sidi, PhD18; Burak Gumuscu, MD, PhD18; Niroshini Naicker, MD19; Gilberto de Castro Jr, MD, PhD20
Source: https://doi.org/10.1200/JCO.23.02625

Dr. Anjan Patel's Thoughts

Based on these findings, Carbo/Taxol+Pembro is an active regimen in met-HNC and an option for those patients who are not good candidates for 5FU based therapy.

PURPOSE

Standard-of-care first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is pembrolizumab plus platinum and fluorouracil (FU). However, FU is associated with potential challenges (continuous 4-day infusion, high administration costs, and cardiovascular and gastrointestinal toxicities), creating a clinical need for alternative chemotherapy combinations. We evaluated the efficacy and safety of first-line pembrolizumab plus carboplatin and paclitaxel for R/M HNSCC in the open-label, single-arm, phase IV KEYNOTE-B10 study (ClinicalTrials.gov identifier: NCT04489888).

METHODS

Eligible adults had previously untreated, histologically or cytologically confirmed R/M HNSCC regardless of PD-L1 status, measurable disease per RECIST v1.1 by blinded independent central review (BICR), and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received pembrolizumab 200 mg intravenously once every 3 weeks for ≤35 cycles and carboplatin AUC 5 mg/mL/min intravenously once every 3 weeks for ≤6 cycles and investigator’s choice of paclitaxel 100 mg/m2 on days 1 and 8 or 175 mg/m2 on day 1, intravenously once every 3 weeks. The primary end point was objective response rate per RECIST v1.1 by BICR.

RESULTS

Between October 27, 2020, and April 29, 2022, 149 patients were screened and 101 received treatment. As of February 20, 2023, the median follow-up was 18.9 months (range, 9.1-27.0). At this final analysis, 49 (49%) of 101 patients had an objective response (95% CI, 38.4 to 58.7), including seven patients (7%) with a confirmed complete response. Of the 101 treated patients, grade 3-5 and serious treatment-related adverse events occurred in 76 (75%) and 27 (27%), respectively. There were no new safety signals.

CONCLUSION

Pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity and a manageable safety profile in first-line R/M HNSCC, suggesting this combination may be an alternative option for this patient population.

Author Affiliations

1Cancer Department, Gold Coast University Hospital, Southport, QLD, Australia; 2Department of Oncology, IDIM Instituto de Diagnóstico e Investigaciones Metabólicas, Buenos Aires, Argentina; 3Department of Oncology, Fundación Respirar, Buenos Aires, Argentina; 4Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada; 5Department of Medical Oncology, Sidney Kimmel Cancer Center at Jefferson-Abington Hospital, Philadelphia, PA; 6Department of Oncology, Hospital Provincial del Centenario, Rosario, Argentina; 7Department of Hematology/Oncology and Palliative Medicine, VCU Massey Cancer Center, Richmond, VA; 8Department of Hematology/Oncology, UC Davis Medical Center, Sacramento, CA; 9Department of Oncology, Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, ON, Canada; 10Department of Oncology, Centro Regional Integrado de Oncologia, Fortaleza, Brazil; 11Department of Oncology, Washington University School of Medicine, St Louis, MO; 12Department of Oncology, CETUS Oncologia, Belo Horizonte, Brazil; 13Yale University School of Medicine and Yale Cancer Center, New Haven, CT; 14Department of Oncology, Oncosite Centro de Pesquisa Clínica em Oncologia, Ijuí, Brazil; 15Department of Hematology and Oncology, Orlando Health Cancer Institute, Orlando, FL; 16Department of Medical Oncology, The Townsville University Hospital, Douglas, QLD, Australia; 17Dr. H. Bliss Murphy Cancer Centre, St John’s, NL, Canada; 18Merck & Co, Inc, Rahway, NJ; 19Oncology European Clinical Development, MSD (UK) Limited, London, United Kingdom; 20Clinical Oncology, Instituto do Câncer do Estado de São Paulo—ICESP, São Paulo, Brazil

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation

Phase II/III study of weekly docetaxel+RT vs. RT alone in cis-ineligible patients. This study was done in India, where oral cancers are an epidemic and possibly biologically unique, as most are related to the use of oral tobacco + betel nut products. >70% of patients were stage IVA / IVB, and HPV was only positive in 4% of patients. Still, the survival benefit was sizeable, and the treatment was tolerable. This is a good option for cis-ineligible HPV-neg patients with bulky disease.

Read More »

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score

Again, further evidence of continued efficacy and tolerability of IO and IO/chemotherapy in SCCHN as compared to EGFR-blockade/chemotherapy. The PD-L1 negative space remains a more difficult scenario, hence new biomarkers are critically important. The long-term response and CR of a percentage of patients are real and intriguing (patient characteristics leading to such response).

Read More »

Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy

Given relatively low-toxicities of capecitabine, it is reasonable to consider it especially in a population with fewer comorbidities and preserved performance-status. More data pertaining OS differences will be welcome. Study is relatively small but not unusual for this diagnosis.

Read More »